medmix AG
medmix AG Fundamental Analysis
medmix AG (MEDX.SW) shows weak financial fundamentals with a PE ratio of 56.12, profit margin of 1.43%, and ROE of 1.51%. The company generates $0.4B in annual revenue with weak year-over-year growth of -0.55%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 21.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze MEDX.SW's fundamental strength across five key dimensions:
Efficiency Score
WeakMEDX.SW struggles to generate sufficient returns from assets.
Valuation Score
ModerateMEDX.SW shows balanced valuation metrics.
Growth Score
WeakMEDX.SW faces weak or negative growth trends.
Financial Health Score
ExcellentMEDX.SW maintains a strong and stable balance sheet.
Profitability Score
ModerateMEDX.SW maintains healthy but balanced margins.
Key Financial Metrics
Is MEDX.SW Expensive or Cheap?
P/E Ratio
MEDX.SW trades at 56.12 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, MEDX.SW's PEG of 0.26 indicates potential undervaluation.
Price to Book
The market values medmix AG at 0.84 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.95 times EBITDA. This is generally considered low.
How Well Does MEDX.SW Make Money?
Net Profit Margin
For every $100 in sales, medmix AG keeps $1.43 as profit after all expenses.
Operating Margin
Core operations generate 6.12 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.51 in profit for every $100 of shareholder equity.
ROA
medmix AG generates $0.66 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
medmix AG produces operating cash flow of $67.80M, showing steady but balanced cash generation.
Free Cash Flow
medmix AG produces free cash flow of $33.30M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.82 in free cash annually.
FCF Yield
MEDX.SW converts 9.27% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
56.12
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.26
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.84
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.80
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.92
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.54
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.007
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How MEDX.SW Stacks Against Its Sector Peers
| Metric | MEDX.SW Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 56.12 | 25.81 | Worse (Expensive) |
| ROE | 1.51% | 1255.00% | Weak |
| Net Margin | 1.43% | -46749.00% (disorted) | Weak |
| Debt/Equity | 0.92 | 0.78 | Neutral |
| Current Ratio | 1.54 | 10.04 | Neutral |
| ROA | 0.66% | -1492798.00% (disorted) | Weak |
MEDX.SW outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews medmix AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
16.38%
Industry Style: Cyclical, Value, Infrastructure
High GrowthEPS CAGR
-129.71%
Industry Style: Cyclical, Value, Infrastructure
DecliningFCF CAGR
-1.66%
Industry Style: Cyclical, Value, Infrastructure
Declining